Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Severe Ulcerative Colitis
Interventions
DRUG

Visilizumab

Trial Locations (11)

10021

Weill Medical College of Cornell, New York

10029

Mount Sinai School of Medicine, New York

15261

University of Pittsburgh Medical Center, Pittsburgh

19104

UPHS/Presbyterian Medical Center, Philadelphia

30342

Atlanta Gastroenterology Associates, Atlanta

55905

Mayo Clinic Rochester, Rochester

60611

Northwestern University, Chicago

60637

University of Chicago Medical Center, Chicago

77555

University of Texas Medical Branch, Galveston

90048

Inflammatory Bowel Disease Center, Los Angeles

94115

University of California, San Francisco, San Francisco

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

PDL BioPharma, Inc.

INDUSTRY

lead

Facet Biotech

INDUSTRY

NCT00267306 - Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis | Biotech Hunter | Biotech Hunter